A Phase I Study Evaluating the Safety, Pharmacokinetics, Tissue Distribution, and Determination of Radiation Dosimetry for 131-I-MIP-1145.
Phase of Trial: Phase I
Latest Information Update: 11 Oct 2011
At a glance
- Drugs Ioflubenzamide I-131 (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions; Pharmacokinetics
- 11 Oct 2011 Planned end date changed from 1 Dec 2010 to 1 Sep 2011 as reported by ClinicalTrials.gov.
- 11 Oct 2011 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 05 May 2010 Planned end date changed from 1 Jul 2010 to 1 Dec 2010 as reported by ClinicalTrials.gov.